Comparisons of Outcomes between Eligible and Ineligible Patients
with CHADS2 Score≥2
At 4 years, 59% of patients had completed follow-up, and the median
follow-up duration was 3.9 years. The cumulative incidence of major
bleeding at 4 years in the eligible and ineligible groups was 7.0% and
13.4%, respectively (Figure 2a ). The risk of major bleeding in
ineligible patients with CHADS2 score ≥2 was almost
double that of eligible patients and statistically significantly higher
(Table 4 ). The 4-year
cumulative stroke and systemic embolism incidence in the eligible and
ineligible groups was 5.5% and 7.5%, respectively (Figure
2b ). Notably, both groups had a CHADS2 score of ≥2;
however, the risk of stroke/SE was significantly higher in ineligible
patients than in eligible patients (Table 4 ). At 4 years, the
cumulative incidence of death from any cause in the eligible and
ineligible groups was 7.3% and 17.6%, respectively (Figure
1c ). The risk of death from any cause in ineligible patients was
approximately three times higher than that in eligible patients
(Table 4 ).